1. F15063, a novel antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: III) Duration of brain D2-like receptor occupancy, antipsychotic-like activity and plasma concentration in rodents;Assie;Neuropsychopharmacology,2006
2. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade;Auclair;Neuropsychopharmacology,2006a
3. Comparative analysis of typical, atypical, and novel antipsychotics with preferential D2/D3 and 5-HT1A affinity in rodent models of cognitive flexibility and sensory gating: (II) The reversal learning task and PPI of the startle reflex;Auclair;Int J Neuropsychopharmacol,2006b
4. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics;Bantick;J Psychopharmacol,2001
5. Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1a activity: comparison with typical and atypical conventional antipsychotics;Bardin;Behav Pharmacol